Comparison of Apixaban Versus Enoxaparin - Trial NCT06243510
Access comprehensive clinical trial information for NCT06243510 through Pure Global AI's free database. This phase not specified trial is sponsored by Abramson Cancer Center at Penn Medicine and is currently Enrolling by invitation. The study focuses on Bladder Cancer. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Abramson Cancer Center at Penn Medicine
Timeline & Enrollment
N/A
Nov 24, 2023
Jul 01, 2025
Primary Outcome
Adherence
Summary
The goal of this randomized trial is to compare bladder cancer patient experiences taking
 prophylactic anticoagulation at home after surgery to remove their bladder. The main
 questions it aims to answer are:
 
 - Are patients equally adherent to apixaban as they are enoxaparin? Why or why not?
 
 - Do patients prefer apixaban or enoxaparin?
 
 - What is the typical patient cost to take apixaban vs enoxaparin after surgery?
 
 Participants will be randomized to receive a prescription for either enoxaparin or apixaban
 which they will then fill themselves and self-administer at home until post-operative day 30.
 They will receive phone calls from study coordinators at days 30 and 90 to complete
 questionaries over the phone to assess trial outcomes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06243510
Non-Device Trial